Vianex SA

HQ: Athens, Greece

Founded in: 1924

Web: www.vianex.gr

VIANEX SA is acknowledged as a pioneer of the Greek pharmaceutical industry. The company is privately owned and has four specialised manufacturing plants. Its affiliate company, VIAN, is dedicated to the marketing and distribution of OTC products and food supplements.

The company’s main areas of business are:

• Strategic alliances with international pharmaceutical companies
• Sales and marketing, and key account management
• Market access
• Pricing and reimbursement
• Regulatory affairs
• Medical information and pharmacovigilance
• Logistics
• Export and toll manufacture

Therapeutic Areas

Vianex SA

• Gastroenterology
• Anti-infectives
• Neurology/psychiatrics
• Hypertension
• Vaccines
• Urology
• Cholesterol
• Blood derivatives
• Asthma and respiratory
• Dermatology
• Oncology
• Ophthalmology
• Osteoporosis
• Contrast media
• Diagnostics
• Anti-inflammation/non-steroidal anti-inflammatory drugs
• Antidiabetics
• Biotechnological
• Hospital products

VIAN SA

• Nutraceuticals
• Antiseptics
• Diagnostics
• Pain/analgesics
• Infant nutrition
• Skin care

Target groups

• Hospital and private practice specialists, general practitioners, specialist nurses, hospital and retail pharmacists, wholesalers, insurance funds
• Established networks with key opinion leaders, decision makers, regulators

Business Units

• Four autonomous divisions, each comprising business units grouped according to therapeutic affinity or common target audience

Key data

• Net sales (2017): €252,3 million
• Production volume: 111 million trade units
• 1,100 employees (of which, 450 in the marketing and sales departments)